Larkin Unpacks the Effect of Anti–PD-L1 Therapy on TIL Activity in Melanoma
Source: OncLive, December 2021
The role of adoptive cell therapy with tumor-infiltrating lymphocytes (TILs) for patients with melanoma has undergone scrutiny as efforts to unpack the correlation between the duration of prior immunotherapy and efficacy outcomes.
Although billed as a personalized approach to care once the manufacturing process genetically alters a patient’s own T cells to fight their disease, there is not a one-size-fits-all eligibility standard for investigators to reference and incorporate TIL therapy into the treatment paradigm for advanced melanoma. Data from several studies have further confused the issue as investigators have reported conflicting conclusions from patient populations which seemingly overlap.
As it stands, prognostic markers in melanoma are limited. The best characterized mutation to date in melanoma is BRAF, which is present in up to 60% of patients with melanoma.4 No approved treatments are available for those who experience disease progression on or after treatment with an immune-checkpoint inhibitor (ICI) and BRAF/MEK inhibitors. Treatment avenues for this patient population include rechallenge with an ICI or chemotherapy, both of which have poor response rates.
READ THE ORIGINAL FULL ARTICLE